{Reference Type}: Journal Article
{Title}: In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus, and Blastomyces emzantsi clinical isolates.
{Author}: Nzimande SP;Govender NP;Maphanga TG;
{Journal}: Antimicrob Agents Chemother
{Volume}: 67
{Issue}: 12
{Year}: 2023 12 14
{Factor}: 5.938
{DOI}: 10.1128/aac.01104-23
{Abstract}: We performed in vitro antifungal susceptibility testing of manogepix against the yeast phase of 78 Emergomyces africanus, 2 Emergomyces pasteurianus, and 5 Blastomyces emzantsi isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.